Inhalation Sciences Q2 operating loss narrows to SEK 1.75 million; net sales more than doubled to SEK 2.7 million

• Inhalation Sciences Sweden posted Q2 net sales of SEK 2.7 million, more than doubled from a year earlier.
• Operating loss narrowed to SEK 1.75 million, while earnings per share improved to SEK -0.03.
• Order intake climbed to SEK 1.68 million, with a new IRS order worth EUR 117,000 signed in May.
• Management said first-half net sales doubled versus 2025, despite geopolitical uncertainty, US customers favoring domestic technology, and delayed research budgets.
• Financing agreement for loans of up to SEK 4 million was signed to support ongoing talks on a possible combination with interested parties.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhalation Sciences Sweden AB published the original content used to generate this news brief via Cision (Ref. ID: 202608240230BITN____UKPR__SV_20260823-BIT-1011-0) on August 24, 2026, and is solely responsible for the information contained therein.